Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

Farm animals and aquaculture cryopreservation partnership announced

Vitrafy Life Sciences Limited has announced that it has entered a 12-month exclusive agreement...

Babies of stressed mothers likely to get their teeth earlier

Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...

Customised immune cells used to fight brain cancer

Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...

Content from other channels on our network

Afnor acquires HACCP Australia and HACCP International

Solving the limitations for paper packaging with coating strategy

Packserv expands into the US with its packaging machinery

Keeping PEZ tablets rolling consistently with print upgrade

Food-grade upscaling line for 'new food' developments

Carbon-conversion technology creates chemicals for jet fuel

Novel energy storage system to decarbonise buildings

F-Gas Regulation: Turning necessity into opportunity

Tiny gold spheres could improve solar energy harvesting

Methane reduction trial uses nature-based supplement

Siemens introduces industrial metaverse design environment

IFR predicts the top five global robotics trends for 2026

UNSW researchers find uses for textiles and other wastes

Queensland BESS project gets grid connection approval

Local defence manufacturing receives funding boost